Enlivex Therapeutics Ltd. (TLV:ENLV)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
366.00
-12.70 (-3.35%)
Apr 1, 2025, 4:39 PM IDT

Enlivex Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2016
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2016
Selling, General & Admin
4.916.147.16.413.7
Upgrade
Research & Development
10.6219.0118.6912.886.09
Upgrade
Operating Expenses
15.5425.1525.819.299.79
Upgrade
Operating Income
-15.54-25.15-25.8-19.29-9.79
Upgrade
Interest & Investment Income
-1.570.840.120.23
Upgrade
Currency Exchange Gain (Loss)
--1.22-4.1-0.56-2.26
Upgrade
Other Non Operating Income (Expenses)
0.52-0.01-0.01-0.33-0.01
Upgrade
EBT Excluding Unusual Items
-15.01-24.82-29.08-20.06-11.82
Upgrade
Gain (Loss) on Sale of Investments
---1.985.59-
Upgrade
Gain (Loss) on Sale of Assets
--4.24---
Upgrade
Pretax Income
-15.01-29.07-31.06-14.47-11.82
Upgrade
Net Income
-15.01-29.07-31.06-14.47-11.82
Upgrade
Net Income to Common
-15.01-29.07-31.06-14.47-11.82
Upgrade
Shares Outstanding (Basic)
2119181813
Upgrade
Shares Outstanding (Diluted)
2119181813
Upgrade
Shares Change (YoY)
10.44%0.98%3.00%35.62%52.25%
Upgrade
EPS (Basic)
-0.73-1.56-1.69-0.81-0.90
Upgrade
EPS (Diluted)
-0.73-1.56-1.69-0.81-0.90
Upgrade
Free Cash Flow
-13.11-23.76-32.08-19.17-12.03
Upgrade
Free Cash Flow Per Share
-0.64-1.28-1.74-1.07-0.91
Upgrade
EBITDA
-14.99-24.32-25.02-18.74-9.5
Upgrade
D&A For EBITDA
0.550.840.780.550.29
Upgrade
EBIT
-15.54-25.15-25.8-19.29-9.79
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.